30,530 Shares in Becton, Dickinson and Company $BDX Acquired by Strategic Global Advisors LLC

Strategic Global Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 30,530 shares of the medical instruments supplier’s stock, valued at approximately $4,620,000.

A number of other hedge funds have also made changes to their positions in BDX. Auto Owners Insurance Co grew its stake in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $3,721,533,000. Wellington Management Group LLP boosted its holdings in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Becton, Dickinson and Company by 23,219.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after acquiring an additional 4,137,888 shares during the last quarter. Finally, Norges Bank bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, The Goldman Sachs Group dropped their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $190.22 on Thursday. The firm has a market cap of $52.41 billion, a price-to-earnings ratio of 57.30, a PEG ratio of 13.38 and a beta of 0.19. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average price of $164.35 and a 200 day moving average price of $160.49.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the company posted $3.68 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 11,704 shares of company stock valued at $1,963,618. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.